{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:02:24Z","timestamp":1792587744942,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ijcard.2024.132043","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T16:09:03Z","timestamp":1713197343000},"page":"132043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Calcium channel blockers in patients with pulmonary arterial hypertension receiving PAH-specific treatment"],"prefix":"10.1016","volume":"406","author":[{"given":"Kyoko","family":"Hirakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2024.132043_bb0005","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.132043_bb0010","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/hrt.44.3.352","article-title":"Primary pulmonary hypertension: effects of nifedipine","volume":"44","author":"Camerini","year":"1980","journal-title":"Br. Heart J."},{"key":"10.1016\/j.ijcard.2024.132043_bb0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.132043_bb0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.7326\/0003-4819-99-4-433","article-title":"Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation","volume":"99","author":"Rubin","year":"1983","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2024.132043_bb0025","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.132043_bb0030","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1378\/chest.06-2674","article-title":"Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines","volume":"131","author":"Badesch","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2024.132043_bb0035","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2024.132043_bb0040","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.132043_bb0045","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.132043_bb0050","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1183\/09031936.00042107","article-title":"A USA-based registry for pulmonary arterial hypertension: 1982-2006","volume":"30","author":"Thenappan","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijcard.2024.132043_bb0055","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.hlc.2022.09.005","article-title":"Acute vasoreactivity testing and outcomes in pulmonary arterial hypertension: a call for increased testing","volume":"32","author":"Chandrasekara","year":"2023","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.ijcard.2024.132043_bb0060","first-page":"903","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.132043_bb0065","doi-asserted-by":"crossref","first-page":"ytac351","DOI":"10.1093\/ehjcr\/ytac351","article-title":"Pulmonary arterial hypertension sensitive to calcium channel blocker, but not advanced pulmonary hypertension treatment: a case report","volume":"6","author":"Hirakawa","year":"2022","journal-title":"Eur. Heart J. Case Rep."},{"key":"10.1016\/j.ijcard.2024.132043_bb0070","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.rmed.2015.01.004","article-title":"The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: how much do we actually know and how could they be positioned today?","volume":"109","author":"Medarov","year":"2015","journal-title":"Respir. Med."},{"key":"10.1016\/j.ijcard.2024.132043_bb0075","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/2045893217714231","article-title":"Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis","volume":"7","author":"Langleben","year":"2017","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ijcard.2024.132043_bb0080","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1161\/CIRCULATIONAHA.105.601930","article-title":"Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension","volume":"113","author":"Elliott","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.132043_bb0085","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1164\/rccm.200908-1284OC","article-title":"Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation","volume":"181","author":"Girerd","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijcard.2024.132043_bb0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.76.1.135","article-title":"High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy","volume":"76","author":"Rich","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.132043_bb0095","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1164\/ajrccm\/140.6.1623","article-title":"The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health registry on primary pulmonary hypertension","volume":"140","author":"Weir","year":"1989","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.ijcard.2024.132043_bb0100","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0735-1097(91)90556-O","article-title":"High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing","volume":"18","author":"Rich","year":"1991","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2024.132043_bb0105","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1164\/ajrccm.151.2.7842196","article-title":"Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin","volume":"151","author":"Sitbon","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijcard.2024.132043_bb0110","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4103\/2045-8932.83449","article-title":"Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension","volume":"1","author":"Malhotra","year":"2011","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ijcard.2024.132043_bb0115","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00408-019-00318-0","article-title":"Is there value in repeating inhaled nitric oxide vasoreactivity tests in patients with pulmonary arterial hypertension?","volume":"198","author":"Tooba","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.ijcard.2024.132043_bb0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jjcc.2023.01.005","article-title":"Prognostic value of follow-up vasoreactivity test in pulmonary arterial hypertension","volume":"82","author":"Ishii","year":"2023","journal-title":"J. Cardiol."},{"key":"10.1016\/j.ijcard.2024.132043_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12281","article-title":"Frequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: results from the pulmonary vascular disease phenomics study","volume":"13","author":"Naranjo","year":"2023","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ijcard.2024.132043_bb0130","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/eurheartj\/ehq170","article-title":"Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension","volume":"31","author":"Montani","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.132043_bb0135","article-title":"Loss of response to calcium channel blockers after long-term follow-up treatment in patients with idiopathic pulmonary arterial hypertension","volume":"49","author":"Piloto","year":"2023","journal-title":"J. Bras. Pneumol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324006375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324006375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T23:55:39Z","timestamp":1714866939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324006375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":27,"alternative-id":["S0167527324006375"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132043","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcium channel blockers in patients with pulmonary arterial hypertension receiving PAH-specific treatment","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"132043"}}